title: Neutralization of tier-2 viruses and epitope profiling of plasma antibodies from human immunodeficiency virus type 1 infected donors from India.
abstract: Broadly cross neutralizing antibodies (NAbs) are generated in a group of HIV-1 infected individuals during the natural infection, but little is known about their prevalence in patients infected with viral subtypes from different geographical regions. We tested here the neutralizing efficiency of plasma antibodies from 80 HIV-1 infected antiretroviral drug naive patients against a panel of subtype-B and C tier 2 viruses. We detected cross-neutralizing antibodies in approximately 19-27% of the plasma, however the subtype-C specific neutralization efficiency predominated (p = 0.004). The neutralizing activity was shown to be exclusively mediated by the immunoglobulin G (IgG) fraction in the representative plasma samples. Epitope mapping of three, the most cross-neutralizing plasma (CNP) AIIMS206, AIIMS239 and AIIMS249 with consensus-C overlapping envelope peptides revealed ten different binding specificities with only V3 and IDR being common. The V3 and IDR were highly antigenic regions but no correlation between their reciprocal Max50 binding titers and neutralization was observed. In addition, the neutralizing activity of CNP was not substantially reduced by V3 and gp41 peptides except a modest contribution of MPER peptide. The MPER was rarely recognized by plasma antibodies though antibody depletion and competition experiments demonstrated MPER dependent neutralization in two out of three CNP. Interestingly, the binding specificity of one of the CNP (AIIMS206) overlapped with broadly neutralizing mAb 2F5 epitope. Overall, the data suggest that, despite the low immunogenicity of HIV-1 MPER, the antibodies directed to this region may serve as crucial reagents for HIV-1 vaccine design.
authors.affiliation: Department of Biochemistry, C N Centre, All India Institute of Medical Sciences, New Delhi, India.
authors.forename: Raiees
authors.initials: R
authors.lastname: Andrabi
authors.forename: Manju
authors.initials: M
authors.lastname: Bala
authors.forename: Rajesh
authors.initials: R
authors.lastname: Kumar
authors.forename: Naveet
authors.initials: N
authors.lastname: Wig
authors.forename: Anjali
authors.initials: A
authors.lastname: Hazarika
authors.forename: Kalpana
authors.initials: K
authors.lastname: Luthra
mesh_terms: D000328:Adult; D057134:Antibodies, Neutralizing / Q000097:blood* / Q000276:immunology*; D000914:Antibodies, Viral / Q000097:blood*; D000956:Antigens, Viral / Q000276:immunology; D001782:Blood Donors; D003429:Cross Reactions; D018604:Epitope Mapping; D005260:Female; D015700:HIV Envelope Protein gp41 / Q000737:chemistry / Q000276:immunology; D015658:HIV Infections / Q000097:blood*; D015497:HIV-1 / Q000276:immunology* / Q000472:pathogenicity; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007194:India; D008297:Male; D008875:Middle Aged; D055815:Young Adult
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D000956:Antigens, Viral; D015700:HIV Envelope Protein gp41; D007074:Immunoglobulin G; C514787:gp41 protein, Human immunodeficiency virus 1